-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, the official website of NMPA showed that Tianjin Hongri Pharmaceutical Co.
, Ltd.
was approved to market the Nadroparin Calcium Injection, which is a generic version of Category 4, which is deemed to have passed the consistency evaluation
.
Nadroparin calcium injection is an anticoagulant drug, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
, Ltd.
was approved to market the Nadroparin Calcium Injection, which is a generic version of Category 4, which is deemed to have passed the consistency evaluation
.
Nadroparin calcium injection is an anticoagulant drug, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
Nadroparin calcium is an anticoagulant drug administered subcutaneously/intravascularly, which belongs to a kind of low molecular weight heparin
.
.
According to data from Minet.
com, the domestic market of nadroparin calcium injection has continued to expand in recent years.
In 2020, the terminal sales of nadroparin calcium injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 13%.
100 million yuan, a year-on-year increase of 10.
46%; sales in the first half of 2021 exceeded 700 million yuan, a year-on-year increase of 22.
39%
.
com, the domestic market of nadroparin calcium injection has continued to expand in recent years.
In 2020, the terminal sales of nadroparin calcium injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 13%.
100 million yuan, a year-on-year increase of 10.
46%; sales in the first half of 2021 exceeded 700 million yuan, a year-on-year increase of 22.
39%
.
Sales of nadroparin calcium injection in public medical institutions in China (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In addition to the original manufacturer, Aspen, France, there are 6 domestic companies that have production approvals for Nadroparin Calcium Injection, including Qianhong Pharmaceutical, Jianyou Co.
, Ltd.
, Changshan Pharmaceutical, Tianjin Biochemical Pharmaceutical, Shenzhen Saibaoer Bio, and Tianjin Hongri Pharmaceutical.
.
, Ltd.
, Changshan Pharmaceutical, Tianjin Biochemical Pharmaceutical, Shenzhen Saibaoer Bio, and Tianjin Hongri Pharmaceutical.
.
At present, there are only two companies that have passed the evaluation of nadroparin calcium injection, namely Tianjin Biochemical Pharmaceutical and Tianjin Hongri Pharmaceutical
.
.
As a new entrant in the heparin drug market, Hongri Pharmaceutical's first heparin preparation, Enoxaparin Sodium Injection, was mass-produced on December 31, 2021 and was deemed to have been reviewed.
Nadroparin Calcium Injection is the company's second product.
Heparin preparations
.
Nadroparin Calcium Injection is the company's second product.
Heparin preparations
.
Data source: Minet database
On April 6, the official website of NMPA showed that Tianjin Hongri Pharmaceutical Co.
, Ltd.
was approved to market the Nadroparin Calcium Injection, which is a generic version of Category 4, which is deemed to have passed the consistency evaluation
.
Nadroparin calcium injection is an anticoagulant drug, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
, Ltd.
was approved to market the Nadroparin Calcium Injection, which is a generic version of Category 4, which is deemed to have passed the consistency evaluation
.
Nadroparin calcium injection is an anticoagulant drug, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
Nadroparin calcium is an anticoagulant drug administered subcutaneously/intravascularly, which belongs to a kind of low molecular weight heparin
.
.
According to data from Minet.
com, the domestic market of nadroparin calcium injection has continued to expand in recent years.
In 2020, the terminal sales of nadroparin calcium injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 13%.
100 million yuan, a year-on-year increase of 10.
46%; sales in the first half of 2021 exceeded 700 million yuan, a year-on-year increase of 22.
39%
.
com, the domestic market of nadroparin calcium injection has continued to expand in recent years.
In 2020, the terminal sales of nadroparin calcium injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 13%.
100 million yuan, a year-on-year increase of 10.
46%; sales in the first half of 2021 exceeded 700 million yuan, a year-on-year increase of 22.
39%
.
Sales of nadroparin calcium injection in public medical institutions in China (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In addition to the original manufacturer, Aspen, France, there are 6 domestic companies that have production approvals for Nadroparin Calcium Injection, including Qianhong Pharmaceutical, Jianyou Co.
, Ltd.
, Changshan Pharmaceutical, Tianjin Biochemical Pharmaceutical, Shenzhen Saibaoer Bio, and Tianjin Hongri Pharmaceutical.
.
, Ltd.
, Changshan Pharmaceutical, Tianjin Biochemical Pharmaceutical, Shenzhen Saibaoer Bio, and Tianjin Hongri Pharmaceutical.
.
At present, there are only two companies that have passed the evaluation of nadroparin calcium injection, namely Tianjin Biochemical Pharmaceutical and Tianjin Hongri Pharmaceutical
.
.
As a new entrant in the heparin drug market, Hongri Pharmaceutical's first heparin preparation, Enoxaparin Sodium Injection, was mass-produced on December 31, 2021 and was deemed to have been reviewed.
Nadroparin Calcium Injection is the company's second product.
Heparin preparations
.
Nadroparin Calcium Injection is the company's second product.
Heparin preparations
.
Data source: Minet database
On April 6, the official website of NMPA showed that Tianjin Hongri Pharmaceutical Co.
, Ltd.
was approved to market the Nadroparin Calcium Injection, which is a generic version of Category 4, which is deemed to have passed the consistency evaluation
.
Nadroparin calcium injection is an anticoagulant drug, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
, Ltd.
was approved to market the Nadroparin Calcium Injection, which is a generic version of Category 4, which is deemed to have passed the consistency evaluation
.
Nadroparin calcium injection is an anticoagulant drug, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
Nadroparin calcium is an anticoagulant drug administered subcutaneously/intravascularly, which belongs to a kind of low molecular weight heparin
.
.
According to data from Minet.
com, the domestic market of nadroparin calcium injection has continued to expand in recent years.
In 2020, the terminal sales of nadroparin calcium injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 13%.
100 million yuan, a year-on-year increase of 10.
46%; sales in the first half of 2021 exceeded 700 million yuan, a year-on-year increase of 22.
39%
.
hospital hospital hospitalcom, the domestic market of nadroparin calcium injection has continued to expand in recent years.
In 2020, the terminal sales of nadroparin calcium injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 13%.
100 million yuan, a year-on-year increase of 10.
46%; sales in the first half of 2021 exceeded 700 million yuan, a year-on-year increase of 22.
39%
.
Sales of nadroparin calcium injection in public medical institutions in China (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In addition to the original manufacturer, Aspen, France, there are 6 domestic companies that have production approvals for Nadroparin Calcium Injection, including Qianhong Pharmaceutical, Jianyou Co.
, Ltd.
, Changshan Pharmaceutical, Tianjin Biochemical Pharmaceutical, Shenzhen Saibaoer Bio, and Tianjin Hongri Pharmaceutical.
.
enterprise enterprise enterprise, Ltd.
, Changshan Pharmaceutical, Tianjin Biochemical Pharmaceutical, Shenzhen Saibaoer Bio, and Tianjin Hongri Pharmaceutical.
.
At present, there are only two companies that have passed the evaluation of nadroparin calcium injection, namely Tianjin Biochemical Pharmaceutical and Tianjin Hongri Pharmaceutical
.
.
As a new entrant in the heparin drug market, Hongri Pharmaceutical's first heparin preparation, Enoxaparin Sodium Injection, was mass-produced on December 31, 2021 and was deemed to have been reviewed.
Nadroparin Calcium Injection is the company's second product.
Heparin preparations
.
Nadroparin Calcium Injection is the company's second product.
Heparin preparations
.
Data source: Minet database
